菸鹼醯胺核糖 Nicotinamide Riboside × 心血管疾病
The human evidence for nicotinamide riboside in cardiovascular disease consists of only a handful of small, short surrogate-marker RCTs (n=24-94, 6-12 weeks) that consistently raised NAD+ but largely failed their primary endpoints.
The human evidence for nicotinamide riboside in cardiovascular disease consists of only a handful of small, short surrogate-marker RCTs (n=24-94, 6-12 weeks) that consistently raised NAD+ but largely failed their primary endpoints. The 2018 Martens pilot found non-significant whole-group blood-pressure and aortic-stiffness effects, with the widely cited ~8 mmHg systolic drop being an exploratory subgroup finding only; the 2022 HFrEF trial confirmed safety but showed no improvement in six-minute walk, left-ventricular function or quality of life; and the 2025 NR-plus-exercise trial showed NR did not outperform exercise alone. There are no hard cardiovascular-outcome (MI, stroke, mortality) trials, the n=94 study is part-funded by the manufacturer ChromaDex, and Examine has no NR cardiovascular outcome row at all (coverage gap, not a positive grade). Harvard Health is openly skeptical, AHA and ACC do not address NR, and Mayo/Cleveland have no dedicated stance. Evidence exists and is real but is small, mechanistic/surrogate-only and inconsistent, which places it firmly at grade C and near the C/U boundary; it is not strong enough for B and not absent enough for U.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.479
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群幾乎沒有針對「菸鹼醯胺核糖（NR）用於心血管疾病」的第一手討論。整個 NAD+ 前驅物話題被 NMN 壟斷，NR 多被當作 NMN 的同類冷門選項順帶提及，且討論角度幾乎全是抗老／凍齡與價格（「一瓶三千多」），看不到鄉民因心臟、血管、高血壓而服用 NR 的實測心得。零星出現的心血管相關說法多是轉貼自健康媒體或動物實驗（NMN/NAD+ 改善血管彈性等），非在地真實使用經驗。理性派則引用《Science》子刊回顧 25 篇臨床指 NR 抗老／代謝效果幾乎無感。整體屬於『社群討論極少、且無 condition-specific 心血管心得』的冷門狀態，僅能記錄到業配導購與 NR/NMN 混淆等認知問題。
無共識（針對心血管疾病無任何第一手實測；NR 整體在台灣社群討論量極少，零星心得僅圍繞抗老／凍齡且多帶價格抱怨，並被 NMN 話題完全掩蓋）
- 生活型態優化（健康飲食、身體活動、戒菸）
- 史他汀類藥物（適應症族群）
- 戒菸（行為介入合併藥物）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-cardiovascular-disease-INT-nicotinamide-riboside-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "菸鹼醯胺核糖能改善心血管疾病",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}